REVUFORJ (revumenib), FDA Approved for Treatment of Patients with Acute Myeloid Leukemia and Acute Lymphoid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a limited specialty pharmacy provider for REVUFORJ, a first-in-class menin inhibitor for relapsed or refractory acute leukemia with KMT2A translocation.
VANFLYTA (quizartinib), FDA Approved in the U.S. for Newly Diagnosed FLT3-ITD Positive Acute Myeloid Leukemia, Available at Biologics by McKesson
Biologics by McKesson was selected as a specialty pharmacy provider for VANFLYTA, approved for newly diagnosed FLT3-ITD positive acute myeloid leukemia in combination and maintenance settings.